David Wurzer - Profile and Investment Details

Investor Profile

David Wurzer is a Venture Capital, Government Office, Private Equity Firm, Investor based in Stonington, Connecticut, United States with a diverse investment portfolio that includes companies such as ZetrOZ, 454 Life Sciences, CyVek, ReNetX Bio, Response Genetics, Inc. (NASDAQ:RGDX), Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), Summit Therapeutics plc (NASDAQ:SMMT) (LONDON:SUMM), NovaTract Surgical, Standard Diversified, Inc. (f/k/a Strategic Diagnostics, Inc. or SDIX) (NYSE American: SDI), Enko Chem, Dusa Pharmaceuticals, Inc. (NASDAQ:DUSA), Connecticut Innovations, Axerion Therapeutics, . Over time, David Wurzer has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether David Wurzer is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, E-commerce, Accounting, Payments, Sports, Alternative Medicine, Enterprise Software, Consumer Goods, Life Science, Information Services, Information Technology (IT), Analytics, Mobile, Software, Biotechnology, Electronic Health Records (EHR), Health and Hospital Services, Consumer Internet, Consulting, Logistics, Knowledge Management, Medical, SaaS, Media and Entertainment, Point of Sale (POS), Pharmaceuticals may find it worthwhile to explore potential connections with David Wurzer, as their portfolio suggests a familiarity and interest in this area.

Understanding David Wurzer’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.